Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. The Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Vaccinia Immune Globulin Intravenous for counteracting complications associated with the smallpox vaccine; and RSDL (decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; NuThrax, an anthrax vaccine in Phase II clinical trials, which is based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; an
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||-42.32%||Sales Growth - Q/Q||-57%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||3.86%||ROE||6.59%||ROI||4.26%|
|Current Ratio||5.05||Quick Ratio||4.03||Long Term Debt/Equity||0.77||Debt Ratio||0.15|
|Gross Margin||74.31%||Operating Margin||12%||Net Profit Margin||7.71%||Dividend Payout Ratio|
|Cash From Financing Activities||11 M||Cash From Investing Activities||-9.08 M||Cash From Operating Activities||-65.87 M||Gross Profit||44.88 M|
|Net Profit||-21.52 M||Operating Profit||-28.31 M||Total Assets||917.85 M||Total Current Assets||405.81 M|
|Total Current Liabilities||80.3 M||Total Debt||251 M||Total Liabilities||379.97 M||Total Revenue||63.63 M|
|High 52 week||73.24||Low 52 week||42.42||Last close||58.59||Last change||-3.73%|
|RSI||17.18||Average true range||3.15||Beta||0.82||Volume||333.02 K|
|Simple moving average 20 days||-12.99%||Simple moving average 50 days||-10.21%||Simple moving average 200 days||1.34%|
|Performance Week||-9.28%||Performance Month||-17.79%||Performance Quart||-11.63%||Performance Half||9.25%|
|Performance Year||26.93%||Performance Year-to-date||26.08%||Volatility daily||2.45%||Volatility weekly||5.49%|
|Volatility monthly||11.25%||Volatility yearly||38.96%||Relative Volume||180.22%||Average Volume||401.43 K|
|New High||New Low|
2019-03-14 11:21:02 | Life Sciences Pa. reveals awards for its top CEO, top products and deal of the year
2019-02-25 16:20:00 | Emergent BioSolutions Looks to Break $1 Billion
2019-02-22 21:48:03 | Emergent BioSolutions Inc EBS Files 10-K for the Fiscal Year Ended on December 31, 2018
2019-02-22 15:42:04 | Edited Transcript of EBS earnings conference call or presentation 21-Feb-19 10:00pm GMT
2019-02-22 11:26:04 | Emergent EBS Q4 Earnings, Revenues Surpass Estimates
2019-02-21 21:26:08 | Emergent Biosolutions Inc EBS Q4 2018 Earnings Conference Call Transcript
2019-02-21 19:55:12 | Emergent Biosolutions EBS Q4 Earnings and Revenues Surpass Estimates
2019-02-21 19:08:34 | Emergent Biosolutions: 4Q Earnings Snapshot
2019-02-21 16:05:00 | Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-15 07:50:00 | Factors of Influence in 2019, Key Indicators and Opportunity within CVS Health, Solaris Oilfield Infrastructure, SK Telecom Co., Energizer, Emergent Biosolutions, and Quad Graphics — New Research Emphasizes Economic Growth
2019-02-14 11:07:38 | Who Has Been Selling Emergent BioSolutions Inc. NYSE:EBS Shares?
2019-02-14 10:31:03 | Earnings Preview: Emergent Biosolutions EBS Q4 Earnings Expected to Decline
2019-02-12 06:30:00 | Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
2019-02-08 08:02:25 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-01-22 14:18:48 | An extended shutdown could bode poorly for local biotechs
2019-01-22 08:06:53 | See what the IHS Markit Score report has to say about Liberty Global PLC.
2019-01-15 08:05:37 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-01-09 19:02:11 | MoCo economic development officials plan satellite office in Boston
2019-01-09 08:05:42 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2019-01-08 17:20:10 | Emergent EBS Up on '19 View, Posts Preliminary '18 Results
2019-01-07 11:41:40 | Emergent BioSolutions CEO to step down
2019-01-07 10:09:03 | Emergent EBS CEO Abdun Nabi to Retire, Kramer to Succeed
2019-01-04 10:56:42 | Our Take On Emergent BioSolutions Inc.’s NYSE:EBS CEO Salary
2018-12-31 08:10:01 | Emergent EBS Files Application for Emergency Use of NuThrax
2018-12-19 22:35:13 | Hedge Funds Are Buying Emergent Biosolutions Inc EBS
2018-12-18 16:56:34 | U.S. FDA panel backs prescribing opioid overdose reversal drug along with painkillers
2018-12-11 08:05:30 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2018-12-08 08:05:17 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2018-12-05 12:22:55 | Read This Before Judging Emergent BioSolutions Inc’s NYSE:EBS ROE
2018-12-04 08:15:00 | Detailed Research: Economic Perspectives on United Technologies, Walmart, Invitae, Emergent Biosolutions, U.S. Physical Therapy, and Amdocs — What Drives Growth in Today's Competitive Landscape
2018-12-01 09:31:02 | Emergent Biosolutions EBS Up 14.1% Since Last Earnings Report: Can It Continue?
2018-11-29 08:04:11 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2018-11-22 08:02:19 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2018-11-20 09:10:02 | Emergent's EBS Zika Vaccine Candidate Meets Study Endpoint
2018-11-19 17:05:53 | Emergent-Valneva Zika vaccine clears early trial
2018-11-15 08:02:19 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
2018-11-06 15:39:00 | Emergent BioSolutions Nabs Its Acquisition Times 2
2018-11-06 07:00:00 | Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
2018-11-02 12:54:04 | Emergent EBS Q3 Earnings and Revenues Fall Shy of Estimates